Notoginsenoside R1
CAS: 80418-24-2
Ref. TM-T2961
5mg | 68,00 € | ||
10mg | 93,00 € | ||
25mg | 152,00 € | ||
50mg | 222,00 € | ||
100mg | 330,00 € | ||
500mg | 779,00 € | ||
1mL*10mM (DMSO) | 95,00 € |
Información del producto
- Sanqi glucoside R1
- Sanchinoside R1
- (3beta,6alpha,12beta)-20-(beta-D-glucopyranosyloxy)-3,12-dihydroxydammar-24-en-6-yl 2-O-beta-D-xylopyranosyl-beta-D-glucopyranoside
- (3β,6α,12β)-20-(β-<span class="text-smallcaps">D</smallcap>-Glucopyranosyloxy)-3,12-dihydroxydammar-24-en-6-yl 2-O-β-<smallcap>D</smallcap>-xylopyranosyl-β-<smallcap>D</span>-glucopyranoside
- (6beta,8xi,9xi,12alpha,13xi,14beta)-17-[(1S)-1-(beta-D-glucopyranosyloxy)-1,5-dimethylhex-4-en-1-yl]-3,12-dihydroxy-4,4,10,14-tetramethylgonan-6-yl 2-O-beta-D-xylopyranosyl-beta-D-glucopyranoside
- Dammarane, β-<span class="text-smallcaps">D</span>-glucopyranoside deriv.
- Netoginsenoside
- Notoginsenoside R 1
- Notoginsenoside R<sub>1</sub>
- Sanchinoside R<sub>1</sub>
- Ver más sinónimos
- beta-D-Glucopyranoside, (3beta,6alpha,12beta)-20-(beta-D-glucopyranosyloxy)-3,12-dihydroxydammar-24-en-6-yl 2-O-beta-D-xylopyranosyl-
- β-<span class="text-smallcaps">D</smallcap>-Glucopyranoside, (3β,6α,12β)-20-(β-<smallcap>D</smallcap>-glucopyranosyloxy)-3,12-dihydroxydammar-24-en-6-yl 2-O-β-<smallcap>D</span>-xylopyranosyl-
- (3β,6α,12β)-20-(β-D-Glucopyranosyloxy)-3,12-dihydroxydammar-24-en-6-yl 2-O-β-D-xylopyranosyl-β-D-glucopyranoside
- β-D-Glucopyranoside, (3β,6α,12β)-20-(β-D-glucopyranosyloxy)-3,12-dihydroxydammar-24-en-6-yl 2-O-β-D-xylopyranosyl-
- Dammarane, β-D-glucopyranoside deriv.
Notoginsenoside R1 (Sanchinoside R1) has been shown to exhibit antioxidant, antiapoptotic, anti-inflammatory, and immune-stimulatory properties.
Propiedades químicas
Consulta técnica sobre: TM-T2961 Notoginsenoside R1
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.